Key statistics
As of last trade Fagron NV (0HNZ:LSE) traded at 22.30, -6.30% below its 52-week high of 23.80, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.40 |
|---|---|
| High | 22.30 |
| Low | 22.30 |
| Bid | 21.85 |
| Offer | 22.95 |
| Previous close | 22.45 |
| Average volume | 6.52k |
|---|---|
| Shares outstanding | 73.67m |
| Free float | 56.70m |
| P/E (TTM) | -- |
| Market cap | 1.65bn EUR |
| EPS (TTM) | -- |
| Annual div (ADY) | 0.35 EUR |
|---|---|
| Annual div yield (ADY) | 1.56% |
| Div ex-date | May 19 2025 |
| Div pay-date | May 21 2025 |
Data delayed at least 20 minutes, as of Feb 17 2026 13:47 GMT.
More ▼
Announcements
- Fagron continues its outstanding performance in FY 2025 with 9.2% topline growth and 10.9% increase in REBITDA
- Fagron behoudt uitstekende prestaties in boekjaar 2025 met 9,2% omzetgroei en een stijging van de REBITDA met 10,9%
- Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
- Fagron verkrijgt goedkeuring van lokale autoriteiten voor de overname van Vepakum in Brazilië en rondt de overname van Magilab in Hongarije af
- Inside information: Fagron announces the completion of the acquisition of University Compounding Pharmacy in North America
- Voorkennis: Fagron kondigt de afronding van de overname van University Compounding Pharmacy in Noord-Amerika aan
- Disclosure of notification received from BNP Paribas
- Openbaarmaking van kennisgeving ontvangen van BNP Paribas
- Fagron announces the completion of Purifarma
- Fagron kondigt de afronding van de overname van Purifarma aan
More ▼
